EU extends Avastin OK to recurrent platinum-sensitive ovarian cancer
This article was originally published in Scrip
Roche has as expected gained EU approval for Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and gemcitabine) to treat women with first recurrence of platinum-sensitive ovarian cancer. The European Commission's approval follows a positive recommendation for the indication by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in September (scripintelligence.com, 21 September 2012).
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.